DPT Acquires Meda Pharmaceuticals’ Lakewood, New Jersey, Location
News Sep 11, 2014
DPT Laboratories has announced the acquisition of Meda Pharmaceuticals’ Lakewood, New Jersey, facilities.
The acquisition reflects the organization’s recent growth, allowing DPT to expand its footprint in Lakewood by adding two buildings totaling 90,000 square feet of space. The real estate meets the organization’s current need for additional cold storage and a larger analytical laboratory.
“The Meda Pharmaceuticals space allows us to meet the needs of our clients today and beyond,” said Gene Ciolfi, vice president and general manager, Lakewood site operations. “We are also in a better position to explore additional opportunities to further our capabilities from development through commercialization.”
As part of the acquisition, DPT will also absorb Meda Pharmaceuticals’ employees to continue the manufacturing of MUSE®, its urethral suppository product.
“We look forward to transitioning Meda Pharmaceuticals’ personnel to the DPT team,” Ciolfi commented. “Their experience and continued dedication to quality complements our commitment to outstanding client service.”
DPT’s current Lakewood location is one of the organization’s established Centers of Excellence. This center provides aseptic processing suites and filling equipment for small-volume parenterals, ophthalmic preparations, preservative-free nasal sprays and sterile ointments.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
2nd International Conference and Exhibition on Nanomedicine and Drug Delivery
May 21 - May 23, 2018
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018